
neg interim analysi outcom
lower pt
lower pt share maintain
buy rate remov oral gi-restrict integrin specif
antagonist treatment ulcer coliti forecast post
morn news co discontinu phase propel
studi follow neg outcom interim analysi patient
unfortun abnorm high number patient
respons occur placebo arm studi may
led unfavor result interim analysi morn news
certainli neg surpris view co lead
pipelin product candid peak sale potenti excess
await addit detail releas propel expect
day remov estim see
detail studi
view today news setback co think
remain potenti co technolog platform includ
antagonist treatment moderate-to-sever
crohn diseas phase may sign collabor
agreement janssen biotech subsidiari sell pt
analyst dane leon worth paid up-front
addit co inject hepcidin mimet peptid
recent complet phase safeti studi expect enter
phase treatment beta-thalassemia
propel phase studi patient enrol evalu
efficaci safeti vs placebo
treatment period patient receiv daili dose either mg
mg mg placebo specifi studi
protocol go/no-go decis would made independ data
monitor committe dmc follow evalu studi
result first patient enrol
estim cash balanc sheet per
share believ co suffici cash last
valuat arriv pt via dcf analysi see page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
phase propel trial discontinu follow interim analysi
requir condit power success requir
propel phase studi patient enrol first stage evalu efficaci safeti
vs placebo treatment period patient receiv daili dose either mg mg
mg placebo
base interim analysi efficaci safeti data first patient enrol independ
data monitor committe dmc deem trial futil base analysi primari endpoint
clinic remiss call manag highlight unexpectedli high placebo
respons rate might impact futility-bas outcom expect analyz data
efficaci safeti data stage trial show addit detail one month
neg outcom trial interim analysi remov estim
maintain buy rate remov oral gi-restrict integrin specif antagonist
treatment ulcer coliti forecast post morn news co discontinu phase
propel studi follow neg outcom interim analysi patient certainli neg
surpris view co lead pipelin product candid peak sale potenti excess
await addit detail releas propel expect day remov
estim see detail studi
view morn news setback co think remain potenti ptgx
technolog platform includ antagonist treatment moderate-to-sever crohn
diseas phase may sign collabor agreement janssen biotech worth
paid up-front addit co inject hepcidin mimet peptid treatment
iron overload disord recent complet phase safeti studi expect enter phase
treatment beta-thalassemia
lower pt remov dcf analysi
updat estim probability-weight includ antagonist treatment
moderate-to-sever crohn diseas phase target patient popul
patient us recent grant orphan drug exclus fda beta-thalassemia phase
proof-of-concept studi complet end last year healthi volunt show favor toler
profil includ seriou dose-limit toxic
revenu y/i inv termin net dilut per btig estim compani reportsprotagonist inc dcf model
collabor janssen remain valu driver view
develop treatment moderate-to-sever crohn diseas potenti once-a-
day oral treatment target pathway stelara fda approv inject monoclon
antibodi design bind receptor believ prompt greater inflamm
natur interact gi compart cytokin influenti protein effect cell commun
 coordin potenti separ may block interact improv
diseas sever crohn patient target stelara monoclon antibodi immunomodul
jnj second biggest seller sale believ stelara ustekinumab intraven infus subq
inject treatment activ moderate-to-sever crohn sale like continu increas annual
peak
stelara target cytokin thought trigger lymphocyt inflamm
believ could long-term potenti altern stelara crohn stelara patent
expir us eu coincid forecast year approv proof-of-
concept treatment yield diminish amount protein associ cytokin rat colon
arrang janssen could financi lucr
janssen biotech agre may collabor exclus world-wide right relat
believ janssen up-front payment current commit phase
valid drug potenti janssen agre fund bulk clinic trial cost begin phase
estim patent protect co pipelin asset
ptgx peptide-bas platform patent protect cover composit matter
use relat ibd valid patent believ corrobor ptgx agreement
janssen protect cover peptid mimet hepcidin
market model suggest could reach end user sale peak sale
potenti base earli stage clinic develop probabl weight
estim tabl follow page detail assumpt crohn
diseas crohn coliti foundat america estim patient current state either
remiss mild diseas activ patient remiss like avoid flare-up least anoth
year patient remiss experienc relaps twice next year therefor
cd patient popul chronic activ diseas lower uc estim today us market
patient cd current classifi within target popul moderate-to-
sever ex-u estim current market patient present categor
moderate-to-sever
extend co potenti asset outsid ibd
develop co in-hous peptid platform biolog inject hepcidin mimet peptid
design manag iron overload disord beta-thalassemia myelodysplast syndrom md
beta-thalassemia congenit blood disord often requir steadi blood transfus impact
peopl world-wide includ birth babi inherit shortag healthi red blood cell symptom
includ low weight yellow skin eye sever anemia root caus superflu serum iron level
target patient popul patient us recent grant orphan drug
exclus fda beta-thalassemia phase proof-of-concept studi complet end last year
healthi volunt show favor toler profil includ seriou dose-limit toxic
co recent announc fourth compound begin preclin ind enabl studi
risk rate recommend
buy rate price target may prove inaccur due number risk associ earli stage
biotechnolog compani bulk valu tie pipelin candid current clinic
trial valuat heavili reliant project revenu present
limit safeti efficaci data may show toxic may show efficaci larger human studi us fda
european approv guarante co may need run addit studi current consid
within clinic develop timelin
inc statement financi project oper expensescost good soldgross profit oper incom incom expens interest incom fair valu redeem convert prefer stock tranch warrant earn loss tax tax benefits- taxes- net incom loss period applic common basic earn loss per earn loss per averag share outstand weight averag share outstand sourc compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
